Literature DB >> 8811262

What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas.

D Velakoulis1, C Pantelis.   

Abstract

OBJECTIVES: Functional imaging technologies allow assessment of cerebral blood flow, cerebral metabolism, cellular metabolic processes, cerebral receptor density and occupancy. This review examines the contribution of such studies to our understanding of schizophrenia. The role of the frontal lobes, the basal ganglia, the temporal lobes and the neuronal circuits which connect them is examined with respect to this literature.
METHOD: All studies in schizophrenia using positron emission tomography, single photon emission computerised tomography, xenon studies, functional and spectroscopic magnetic resonance imaging formed the basis of this review. Only those studies published in English were reviewed.
RESULTS: The most consistent finding in schizophrenia has been that of hypofrontality, while the results of studies examining subcortical structures provide preliminary support for the concept of fronto-striatal dysfunction. Functional imaging has not yet provided consistent results in the study of temporal lobe function. Although receptor studies have shed light on the actions of antipsychotic medications, the findings for dopamine receptor numbers remain controversial. Spectroscopic and functional MRI remain in their infancy as research tools in schizophrenia.
CONCLUSIONS: Although there are significant methodological issues to be addressed, functional imaging technology is providing increasing insights into schizophrenia and its treatment. Future research will be truly multidisciplinary as it will require the collaboration of psychiatrists, imaging physicians, neuropsychologists and neuroscientists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811262     DOI: 10.3109/00048679609076095

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  7 in total

Review 1.  Functional brain mapping of psychopathology.

Authors:  G D Honey; P C Fletcher; E T Bullmore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia.

Authors:  Céline Risterucci; Karine Jeanneau; Stephanie Schöppenthau; Thomas Bielser; Basil Künnecke; Markus von Kienlin; Jean-Luc Moreau
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

Review 3.  A multilevel analysis of cognitive dysfunction and psychopathology associated with chromosome 22q11.2 deletion syndrome in children.

Authors:  Tony J Simon; Joel P Bish; Carrie E Bearden; Lijun Ding; Samantha Ferrante; Vy Nguyen; James C Gee; Donna M McDonald-McGinn; Elaine H Zackai; Beverly S Emanuel
Journal:  Dev Psychopathol       Date:  2005

4.  Regional cerebral blood flow in late-onset schizophrenia: a SPECT study using 99mTc-ECD.

Authors:  Rei Wake; Tsuyoshi Miyaoka; Tomoko Araki; Kazunori Kawakami; Motohide Furuya; Erlyn Limoa; Sadayuki Hashioka; Jun Horiguchi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-05-27       Impact factor: 5.270

5.  Study of childhood onset schizophrenia (COS) using SPECT and neuropsychological assessment.

Authors:  Savita Malhotra; Nitin Gupta; Anish Bhattacharya; Mehak Kapoor
Journal:  Indian J Psychiatry       Date:  2006-10       Impact factor: 1.759

Review 6.  Neurobiological markers of illness onset in psychosis and schizophrenia: The search for a moving target.

Authors:  Christos Pantelis; Murat Yücel; Emre Bora; Alex Fornito; Renée Testa; Warrick J Brewer; Dennis Velakoulis; Stephen J Wood
Journal:  Neuropsychol Rev       Date:  2009-09       Impact factor: 7.444

7.  Structural brain changes in First Episode Schizophrenia compared with Fronto-Temporal Lobar Degeneration: a meta-analysis.

Authors:  Bayanne Olabi; Ian Ellison-Wright; Ed Bullmore; Stephen M Lawrie
Journal:  BMC Psychiatry       Date:  2012-08-07       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.